Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations
Article first published online: 20 APR 2002
British Journal of Haematology
Volume 103, Issue 1, pages 42–44, October 1998
How to Cite
Brown, K., Luddington, R. and Baglin, T. (1998), Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations . British Journal of Haematology, 103: 42–44. doi: 10.1046/j.1365-2141.1998.00935.x
- Issue published online: 20 APR 2002
- Article first published online: 20 APR 2002
- methylenetetrahydrofolate reductase;
- factor V Leiden;
Odds ratios for the MTHFRC677T variant were determined in a large case–control study of 558 unselected patients with venous thromboembolism and 500 control subjects. The odds ratios for MTHFRC677T heterozygosity and homozygosity were 1.07 (95%CI 0.84–1.36) and 0.71 (95%CI 0.48–1.03). In patients with the factor V Leiden or the F2G20210A mutations there was no apparent increase in risk of venous thromboembolism due to the MTHFRC677T polymorphism.
Thrombophilia testing should not include genotyping for the MTHFRC677T polymorphism.